{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:00:56Z","timestamp":1778958056714,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R56\u2010AR\u2010062615"],"award-info":[{"award-number":["R56\u2010AR\u2010062615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether scleroderma patients who are double\u2010positive for anti\u2013interferon\u2010inducible protein 16 (anti\u2013IFI\u201016) antibodies and anticentromere (anti\u2010CENP) antibodies are at increased risk for significant digital vascular events relative to patients positive for anti\u2010CENP antibodies alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sera from 165 scleroderma patients who tested positive for anti\u2010CENP antibodies upon clinical evaluation were reassayed for both anti\u2010CENP and anti\u2013IFI\u201016 antibodies using enzyme\u2010linked immunosorbent assay testing. Patients who were positive for anti\u2010CENP antibodies alone were then compared to patients who were double\u2010positive for both anti\u2013IFI\u201016 and anti\u2010CENP antibodies. The association between a history of significant digital vascular events (digital pits, ischemic digital ulcers, and\/or gangrene) and double\u2010positive antibody status was examined using chi\u2010square tests. After completion of univariate analysis, multivariable analyses were done to adjust for clinically relevant covariates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 165 anti\u2013CENP antibody positive patients, 21 (12.7%) also had anti\u2013IFI\u201016 antibodies. Patients who were double\u2010positive for anti\u2010CENP and anti\u2010IFI\u201016 antibodies were more likely to have had digital pits, ischemic digital ulcers, and\/or gangrene (<jats:italic>P<\/jats:italic>\u2009=\u20090.03). After adjustment for clinically relevant covariates (age, cutaneous subtype, disease duration, and smoking), double\u2010positive patients remained at significantly higher odds of having severe Raynaud's phenomenon (odds ratio 3.5 [95% confidence interval 1.1\u201311.1]; <jats:italic>P<\/jats:italic>\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Scleroderma patients who are double\u2010positive for antibodies recognizing CENP and IFI\u201016 are significantly more likely to have significant digital vascular events during the course of their disease. This study provides further evidence that anti\u2010CENP and anti\u2013IFI\u201016 antibodies are disease biomarkers that may be used for risk stratification of vascular events in scleroderma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.22978","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T11:17:46Z","timestamp":1467890266000},"page":"922-926","source":"Crossref","is-referenced-by-count":16,"title":["Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti\u2013Interferon\u2010Inducible Protein 16 Antibodies"],"prefix":"10.1002","volume":"69","author":[{"given":"Zsuzsanna H.","family":"McMahan","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick M.","family":"Wigley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Casciola\u2010Rosen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0806188"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350614"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740801978871"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2007.12.001"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005112"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39558"},{"key":"e_1_2_4_8_1","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy EC","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_4_10_1","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger TA","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.1.9712108"},{"key":"e_1_2_4_12_1","first-page":"269","article-title":"Natural history of mild\u2010moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma","volume":"33","author":"Chang B","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10775"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39316"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0493-1"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22978","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:27:41Z","timestamp":1759418861000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/acr.22978"],"URL":"https:\/\/doi.org\/10.1002\/acr.22978","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}